FOLOTYN ® (pralatrexate injection) is the first therapeutic to have been approved for peripheral T-cell lymphoma (PTCL), in September 2009 FOLOTYN net sales were approximately $50 million in 2011 ...

Allos Therapeutics announced the presentation of further data from its Phase 2b study of Folotyn (pralatrexate injection) relative to Tarceva (erlotinib, from Genentech) in patients with Stage IIIB/IV ...

Spectrum Pharmaceuticals confirmed in a filing that it received notification from the FDA of their early action granting accelerated approval of the company’s New Drug Application for Beleodaq for ...

HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in ...

“We are committed to making FOLOTYN available in the EU for patients with relapsed or refractory peripheral T-cell lymphoma -- an aggressive and progressive disease where there remains a high unmet ...

Allos Therapeutics anticipates a January commercial launch for Folotyn, the first and only drug currently approved by the FDA for relapsing or refractory peripheral T-cell lymphoma (rrPTCL). A ...

HENDERSON, Nev. -- Spectrum Pharmaceuticals Inc. said Monday that the U.S. government extended the patent on its lymphoma drug Folotyn by five years. Spectrum said the patent will now expire on July ...

FOLOTYN, a folate analogue metabolic inhibitor, is the first and only drug approved in the United States for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), a ...

FOLOTYN (pralatrexate) 20mg/mL, 40mg/2mL injection by Allos Therapeutics Folotyn (pralatrexate injection) has been made available by Allos Therapeutics for use as a single agent for the treatment of ...

Spectrum Pharmaceuticals Highlights Promising ZEVALIN®, FOLOTYN® and Belinostat Clinical Data Presented at the 54th Annual Meeting of the American Society of Hematology Investigator-sponsored studies ...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced ...